MitoImmune Therapeutics
Seoul, South Korea · $14.4M raised
- Headquarters
- Seoul
- Business Model
- B2B
- Website
- mitoimmune.com
- Total Funding
- $14.4M
- Last Round
- $3.9M Series BSep 2023
- Rounds
- 2
About
Clinical-stage biotech developing mitochondrial and ferroptosis-based therapeutics.
Summary
MitoImmune Therapeutics is a Biotech company based in Seoul, South Korea. It has raised $14.4M in total across 2 rounds, most recently a $3.9M Series B round in Sep 2023. Investors include KB Investment and IMM Investment.
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Funding History
Sep 2023
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company